Pacer Advisors
NRIX icon

Pacer Advisors’s Nurix Therapeutics NRIX Stock Holding History

Pacer Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-781
Closed -$16.3K – 2643
2024
Q2 		$16.3K Sell
781
-204
-21% -$3.18K ﹤0.01% 3466
2024
Q1 		$14.5K Buy
+985
New +$10.6K ﹤0.01% 3489
2021
Q2 		– Sell
-1,581
Closed -$49K – 1499
2021
Q1 		$49K Buy
1,581
+1,042
+193% +$39.4K ﹤0.01% 1440
2020
Q4 		$18K Buy
+539
New +$17.9K ﹤0.01% 1488

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Pacer Advisors's NRIX Position: Q3 2024 in Review

Pacer Advisors sold out of Nurix Therapeutics (NRIX) in Q3 2024, closing a stake of 781 shares — an estimated $16.3K sold.

Pacer Advisors first reported a position in NRIX in Q4 2020 and held it in 4 quarters. The position peaked at $49K in Q1 2021. 172 funds tracked by Wall St. Rank hold NRIX as of Q3 2024.

  • Pacer Advisors reported no remaining Nurix Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 781 Nurix Therapeutics shares in Q3 2024, an estimated $16.3K.
  • Pacer Advisors first reported a position in Nurix Therapeutics in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Nurix Therapeutics position peaked at $49K in Q1 2021.
  • 172 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.